← FDA DRUG APPROVALS

FDA ANDA · ANDA204741

CAPECITABINE

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA204741
TYPE
ANDA
ORIGINAL APPROVAL
2017-02-28
LATEST ACTION
2026-05-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CAPECITABINEDiscontinued
CAPECITABINE 150MG · TABLET · ORAL
CAPECITABINEDiscontinued
CAPECITABINE 500MG · TABLET · ORAL

Approval history

2026-05-07Labeling · Supplement 13 · standardAP
2025-04-09Labeling · Supplement 2 · standardAP
2025-04-09Labeling · Supplement 9 · standardAP
2025-04-09Labeling · Supplement 11 · standardAP
2017-02-28UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →